Dipeptidyl Peptidase 4 Inhibitors: Applications in Innate Immunity?

Roger Yazbek, Simone Jaenisch, Catherine Abbott

Research output: Contribution to journalReview articlepeer-review

21 Citations (Scopus)


Dipeptidyl peptidase (DPP)-4 inhibitors are a class of orally available, small molecule inhibitors that prolong the insulinotropic activity of the incretin hormone glucagon-like peptide-1 (GLP-1) and are highly effective for the treatment of Type-2 diabetes. DPP4 can also cleave several immunoregulatory peptides including chemokines. Emerging evidence continues to implicate DPP4 inhibitors as immunomodulators, with recent findings suggesting DPP4 inhibitors modify specific aspects of innate immunity. This review summarises recent insights into how DPP4 inhibitors could be implicated in endothelial, neutrophil and monocyte/macrophage mediated immunity. Additionally, this review highlights additional avenues of research with DPP4 inhibitors in the context of the COVID-19 pandemic.
Original languageEnglish
Article number114517
Number of pages10
JournalBiochemical Pharmacology
Publication statusPublished - Jun 2021


  • Dipeptidyl peptidase
  • DPP4 inhibitor
  • Sitagliptin
  • Immunity
  • Innate immunity
  • Neutrophil
  • Macrophage


Dive into the research topics of 'Dipeptidyl Peptidase 4 Inhibitors: Applications in Innate Immunity?'. Together they form a unique fingerprint.

Cite this